| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 107.19M | 75.56M | 33.56M | 17.99M | 13.81M | 4.04M | 
| Gross Profit | 94.89M | 62.03M | 23.94M | 10.77M | 10.07M | 1.67M | 
| EBITDA | 2.13M | -561.00K | -6.84M | -8.84M | -5.29M | -8.58M | 
| Net Income | -6.09M | -3.72M | -13.73M | -14.60M | -7.54M | -11.52M | 
| Balance Sheet | ||||||
| Total Assets | 109.97M | 84.54M | 71.46M | 82.95M | 91.34M | 94.36M | 
| Cash, Cash Equivalents and Short-Term Investments | 17.90M | 17.46M | 14.21M | 24.07M | 28.62M | 28.39M | 
| Total Debt | 1.79M | 1.79M | 2.14M | 1.91M | 2.15M | 2.34M | 
| Total Liabilities | 33.32M | 25.79M | 14.75M | 14.09M | 14.36M | 9.76M | 
| Stockholders Equity | 76.65M | 58.75M | 56.71M | 68.86M | 76.98M | 84.60M | 
| Cash Flow | ||||||
| Free Cash Flow | -787.00K | 2.03M | -9.17M | -7.75M | -5.83M | -9.46M | 
| Operating Cash Flow | 779.00K | 3.14M | -8.84M | -7.35M | -5.45M | -9.24M | 
| Investing Cash Flow | -1.57M | -1.11M | -326.00K | -400.00K | -374.00K | -220.00K | 
| Financing Cash Flow | 1.65M | 1.34M | -171.00K | 3.22M | 6.08M | 17.08M | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | CHF561.52M | 7.82 | ― | ― | 58.51% | ― | |
| ― | $285.04M | 11.92 | ― | ― | 744.64% | ― | |
| ― | $1.10B | -183.95 | -7.82% | ― | 104.01% | 33.25% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $119.11M | -1.64 | -48.90% | ― | -91.34% | -2.84% | |
| ― | $140.58M | 2.58 | -301.13% | ― | -56.85% | -186.55% | |
| ― | CHF838.81M | -4.62 | ― | ― | 67.18% | -480.10% | 
Kuros Biosciences announced a 77% year-over-year increase in revenue for the first nine months of 2025, driven by strong sales of its MagnetOs products. The company has launched the MagnetOs MIS Delivery System in the U.S., following FDA clearance, and received approval for MagnetOs products in Saudi Arabia, marking significant milestones in its strategic expansion and positioning in the medical device industry.
The most recent analyst rating on (CH:KURN) stock is a Hold with a CHF25.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
Kuros Biosciences is addressing media inquiries regarding the resignation of former Board member Albert Arp, who allegedly shared price-sensitive information with an unrelated third party. The company is conducting an internal investigation but assures that this issue does not affect its strategic direction, financial results, or operations.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
Kuros Biosciences announced changes to its Board of Directors, with Albert Arp resigning and Oliver Walker and Kimberley Elting taking on new roles within the board. These changes could impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder relations.
The most recent analyst rating on (CH:KURN) stock is a Hold with a CHF28.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
Kuros Biosciences, a Swiss-based company, specializes in the development and commercialization of innovative biological technologies for musculoskeletal care, with a focus on bone grafting solutions.
Kuros Biosciences reported a 78% increase in total medical device sales for the first half of 2025, achieving its first-ever operating profit. The company has seen substantial growth in its MagnetOs product line, supported by strategic partnerships, FDA clearances, and international market expansion. Kuros is well-positioned for continued growth, with expectations of robust sales increases and further market penetration, particularly in the U.S. and emerging markets.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.